Baclofen is a centrally acting gamma aminobutyric acid (GABA)-B agonist, widely used for chronic spasticity in neurological disorders, available in oral and intrathecal formulations. Depending on the severity of spasticity and tolerance, standard treatment includes daily oral administration of 40–80 mg [1]. The main adverse effects reported with baclofen are sedation, sleepiness, weakness, dizziness and psychological disturbances [2]. According to the depressant effects of GABA on the central nervous system, baclofen might also induce or aggravate sleep-disordered breathing by depressing central ventilatory drive and/or increasing upper airway obstruction. A single oral low dose of baclofen did not significantly impair the apnoea–hypopnoea index (AHI) in a population with moderate obstructive sleep apnoea [3], but bolus intrathecal administration of the drug increased central sleep apnoea (CSA) in patients with severe spasticity [4]. Baclofen is associated with sleep apnoea syndrome especially the high oral doses prescribed for alcohol addiction http://ow.ly/J5H730h4znW

中文翻译：

---

巴氯芬和睡眠呼吸暂停综合征：WHO 药物警戒数据库 VigiBase 的分析

巴氯芬是一种中枢作用的 γ-氨基丁酸 (GABA)-B 激动剂，广泛用于神经系统疾病的慢性痉挛，可用于口服和鞘内制剂。根据痉挛和耐受的严重程度，标准治疗包括每日口服 40-80 mg [1]。据报道，巴氯芬的主要不良反应是镇静、嗜睡、虚弱、头晕和心理障碍 [2]。根据 GABA 对中枢神经系统的抑制作用，巴氯芬还可能通过抑制中枢通气驱动和/或增加上呼吸道阻塞来诱发或加重睡眠呼吸障碍。在中度阻塞性睡眠呼吸暂停患者中，单次口服低剂量巴氯芬不会显着损害呼吸暂停-低通气指数 (AHI) [3]，但在严重痉挛患者中，鞘内推注药物会增加中枢性睡眠呼吸暂停 (CSA) [4]。巴氯芬与睡眠呼吸暂停综合征有关，尤其是酒精成瘾的高口服剂量 http://ow.ly/J5H730h4znW